| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -226,445 | -145,515 |
| Depreciation and amortization expense | 1,936 | 1,295 |
| Stock-based compensation expense | 30,328 | 19,724 |
| Amortization of operating leases, right-of-use assets | 1,506 | 1,000 |
| Net amortization (accretion) of premiums (discounts) on marketable securities | 906 | 739 |
| Amortization of long-term debt discount and issuance costs | 363 | 63 |
| Prepaid expenses and other current assets | -3,041 | -2,235 |
| Other assets | -374 | 0 |
| Accounts payable | 4,016 | 4,612 |
| Accrued expenses and other current liabilities | 1,586 | -2,979 |
| Operating lease liability | -1,158 | -758 |
| Other liabilities | 20 | 9 |
| Net cash used in operating activities | -185,339 | -121,053 |
| Purchases of property and equipment | 743 | 678 |
| Purchases of marketable securities | 291,949 | 67,883 |
| Maturities and sales of marketable securities | 215,935 | 146,850 |
| Net cash used in investing activities | -76,757 | 78,289 |
| Proceeds from long-term debt | 49,291 | 49,291 |
| Payment of debt issuance costs | 2,304 | 2,069 |
| Proceeds from issuance of common stock under atm, net of issuance costs of 0.7 million | 24,250 | 24,250 |
| Proceeds from issuance of common stock in public offering, net of offering costs of 14.3 million | 215,792 | - |
| Proceeds from issuance of common stock and series b preferred stock in connection with the private placement, net of offering costs of 11.6 million | 0 | 0 |
| Proceeds from issuance of common stock upon stock option exercises | 1,185 | 141 |
| Proceeds from issuance of stock from employee stock purchase plan | 1,350 | 584 |
| Net cash provided by financing activities | 289,564 | 72,197 |
| Net increase in cash, cash equivalents and restricted cash | 27,468 | 29,433 |
| Cash and cash equivalents at beginning of period | 98,165 | - |
| Cash and cash equivalents at end of period | 125,633 | - |
Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (COGT)